Medytox Inc.

Gi Hyeok Yang

Hyun Ho Jung

Chang Hoon Rhee

Hack Woo Kim

Hyun Jee Kim

Hee Dong Woo

Junho Lee

Sujin Cho

Sung Bum Kim

Seung Hwan Baek

Jun Ho Lee

Young Rae Lee

Hyung Pyo Hong

Jung Hyun Song

Cheon Soo Lim

Joon Chan Kong

Gi Hyuck Ryu

Dong Kyu Lee

The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer lasting effect in the patient compared to an animal-protein-containing botulinum toxin composition.

Long lasting effect of new botulinum toxin formulations

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate, and methionine and optionally isoleucine. The liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients, has good storage stability of botulinum toxin at 25˜37° C., as well as at refrigerated temperatures.

Pharmaceutical liquid composition of botulinum toxin with improved stability

The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.

Methods and compositions of bile acids and salts for reduction of fat

Provided is a method of isolating a botulinum toxin type A macro complex from a botulinum toxin-containing solution, the method including performing anion exchange chromatography and cation exchange chromatography.

Method of isolating botulinum toxin from botulinum toxin-containing solution

Provided are a recombinant polynucleotide encoding a polypeptide including a reporter moiety, a substrate moiety, and a destabilization moiety, a host cell including the same, and use thereof to measure the level of a protease by using the recombinant polynucleotide.

Recombinant polynucleotide coding for polypeptide comprising reporter moiety, substrate moiety and destabilizing moiety, host cell comprising same and use of same

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25&#x2dc;37&#xb0; C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without lyophilization process.

Pharmaceutical liquid composition of botulinum toxin with improved stability and method of use

Provided are a temperature sensitive adhesion prevention composition and a method for producing the same, the composition comprising a polyethylene oxide (PEO) containing copolymer, a carboxy polysaccharide, and a monovalent cation.

Temperature sensitive adhesion prevention composition and use thereof

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25&#x2dc;37&#xb0; C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without a lyophilization process.

There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.

Growing community of inventors

Chungcheongnam-do, South Korea

Gi Hyeok Yang